secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0001837607-24-000077
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma shifts ABP-450 to biosimilar pathway targeting BOTOX; plans pivotal study in cervical dystonia
--------------------------------------------------------------------------------

- ABP-450 will pursue 351(k) biosimilar pathway using AbbVie's BOTOX as reference product.
- Company plans a single pivotal Phase 3 comparative study in cervical dystonia.
- Successful Phase 3 could support biosimilar determination for up to 8 therapeutic indications.
- Biosimilar Initial Advisory Meeting with FDA scheduled for Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000077/0001837607-24-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000077/aeon-20240709x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-24-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer